Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)

Details

Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.

After completing Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018) physicians will better be able to:

• Summarize the most impactful findings presented at EHA 2018 meeting relating to initial treatment of transplant eligible and ineligible myeloma
• Summarize the most impactful findings presented at EHA 2018 meeting relating to role of autologous stem cell transplant
• Summarize the most impactful findings presented at EHA 2018 meeting relating to current role of monoclonal antibodies
• Summarize the most impactful findings presented at EHA 2018 meeting relating to novel immune therapies

Target Audience: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.